logo
Jewish Healthcare Foundation Releases Report on Self-Directed Patient Safety Technology

Jewish Healthcare Foundation Releases Report on Self-Directed Patient Safety Technology

Business Wire28-05-2025
PITTSBURGH--(BUSINESS WIRE)--The technology exists for patients and families to prevent a medication error, understand what symptoms present a potentially serious condition, avoid an emergency room or hospital visit, schedule an appointment with a local specialist of high quality—all from their phone or wearable device. In a new report released today by the Jewish Healthcare Foundation (JHF), the opportunities are clear for individuals and families to play a more active role in protecting their health through emerging technologies and digital tools.
'As the healthcare system faces unprecedented financial and human pressures, self-directed safety is a scalable, patient-centered solution.'
The report, Self-Directed Patient Safety: Mapping the Emerging Landscape of Consumer-Facing Innovation, developed in partnership with TEConomy Partners, LLC, comes at a critical time: medical errors remain the third leading cause of death in the United States, healthcare spending continues to rise faster than the economy, and chronic illness affects six in ten Americans. Amid these unsustainable trends, JHF's new report identifies self-directed patient safety —the empowerment of patients to prevent harm and manage care through direct-to-consumer technologies—as a promising strategy for improving outcomes while reducing costs.
'This is a generational opportunity to rethink how we approach patient safety,' said Karen Wolk Feinstein, PhD, President and CEO of the Jewish Healthcare Foundation and Pittsburgh Regional Health Initiative. 'By putting modern tools directly in patients' hands—like AI-powered symptom checkers, smart medication dispensers, and remote monitoring devices—we can shift from a reactive system to one focused on prevention, engagement, and shared responsibility.'
She continues, 'Over a decade ago, our Foundation identified four interventions that would dramatically reduce hospitalizations: managing chronic conditions in the community, greater medication scrutiny, addressing behavioral health issues as early as possible, and engaging patients in advancing their health. The first three have gotten more attention; patient engagement remains a promising but underdeveloped opportunity.'
The report explores five key areas where preventable harm often occurs—medication errors, patient care errors, diagnostic errors, infection errors, and surgical errors—and showcases timely innovations across these domains. It also outlines the market forces, regulatory barriers, and investment trends shaping the future of self-directed safety.
Key findings include:
Growing innovation and venture capital activity in consumer health tech, particularly in AI-driven health IT and digital platforms.
Notable solutions are being developed to support high-risk groups such as aging adults, new parents, individuals with chronic diseases, and rare disease patients.
Significant regulatory and economic challenges slowing adoption of direct-to-consumer safety tools—yet also opportunities for leadership in regions like Pittsburgh, which combine world-class health care with technology innovation.
The report's release supports JHF's broader mission to advance patient safety and innovation in health care. It aligns closely with recent priorities from the CMS Innovation Center, including empowering people to achieve health goals, encouraging evidence-based prevention, and leveraging technology to improve care delivery.
'As the healthcare system faces unprecedented financial and human pressures, self-directed safety is a scalable, patient-centered solution,' added Dr. Feinstein. 'We hope this report sparks new partnerships, policies, and products that empower people to protect themselves and their loved ones.'
The full report is available at jhf.org.
Available for Interviews: Karen Wolk Feinstein, PhD, President and CEO, Jewish Healthcare Foundation
About the Jewish Healthcare Foundation
The Jewish Healthcare Foundation (JHF) and its three operating arms — the Pittsburgh Regional Health Initiative (PRHI), Health Careers Futures (HCF), and the Women's Health Activist Movement Global (WHAMglobal) — offer a unique brand of activist philanthropy to advance healthcare innovation, advocacy, collaboration, and education in the interest of better health. For more information, visit jhf.org.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

MTTI Announces Dr. Danielle Meyrick to Lead Medical Team
MTTI Announces Dr. Danielle Meyrick to Lead Medical Team

Yahoo

time33 minutes ago

  • Yahoo

MTTI Announces Dr. Danielle Meyrick to Lead Medical Team

WEST CHESTER, Pa., July 22, 2025--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI) today announced the appointment of Danielle Meyrick, PhD, MD, as Chief Medical Officer. Dr. Meyrick brings more than 20 years of medical research, targeted radiotherapeutic (TRT) development and leadership to MTTI. She has held Chief Medical Officer roles across radiopharmaceutical organizations including Telix Pharmaceuticals and ITM Radiopharm. Dr. Meyrick will lead MTTI's medical team to advance clinical development of lead assets, EVA101 and EVA 102 and further progress the company's radiopharmaceutical pipeline. "My career goal in the TRT area has always been to improve care and outcomes for cancer patients. I believe MTTI is an exciting company with technology that is able to deliver on this goal. Our unique EvaThera platform has demonstrated the ability to enhance delivery of radiation to tumors, minimize off-target activity and reduce dosing requirements —collectively offering a potentially safer, more effective approach to TRT. I am thrilled to be supporting the team in leading EVA101 and EVA102 through the critical final stages of development," said Danielle Meyrick, CMO of MTTI. Dr. Chris Pak, President & CEO commented "MTTI is delighted to welcome Dr. Danielle Meyrick, an experienced clinician and executive. Her perspective and track record in TRT development are key complements to our team as we expedite advancement of our targeted radiotherapeutic pipeline." Molecular Targeting Technologies, Inc. (MTTI). MTTI is a private, clinical stage biotech developing targeted radiotherapeutics (TRT). MTTI is committed to building value by translating innovative TRT to improve human healthcare. For more information: View source version on Contacts Chris Pak, Email: cpak@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

HealthStream to Host Second Quarter 2025 Earnings Conference Call
HealthStream to Host Second Quarter 2025 Earnings Conference Call

Business Wire

time40 minutes ago

  • Business Wire

HealthStream to Host Second Quarter 2025 Earnings Conference Call

NASHVILLE, Tenn.--(BUSINESS WIRE)--HealthStream, Inc. (Nasdaq: HSTM), a leading healthcare technology platform company for workforce solutions, announced today that it will host a conference call and webcast to discuss its second quarter 2025 financial results on Tuesday, August 5, 2025. The Company's financial results for the second quarter 2025 ended June 30, 2025 will be released after the routine time for the close of the market on Monday, August 4, 2025. HealthStream's second quarter 2025 earnings conference call will begin at 9:00 a.m. Eastern Time on Tuesday, August 5, 2025. Participants may access the conference call live via webcast using this LINK. To participate via telephone, please register in advance using this LINK. Upon registration, all telephone participants will receive a one-time confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. All participants are instructed to dial-in 15 minutes prior to the start time. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days. About HealthStream HealthStream (Nasdaq: HSTM) is the healthcare industry's largest ecosystem of platform-delivered workforce solutions that empowers healthcare professionals to do what they do best: deliver excellence in patient care. For more information, visit or call 615-301-3100. This press release contains forward-looking statements that involve risks and uncertainties regarding HealthStream. This information has been included in reliance on the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such results or events predicted in these statements may differ materially from actual future events or results. These forward-looking statements are based on a variety of assumptions that may not be realized, and which are subject to significant risks and uncertainties, including that the anticipated financial and strategic benefits of the acquisition may not be realized, as well as risks and uncertainties referenced from time to time in the Company's filings with the Securities and Exchange Commission.

MTTI Announces Dr. Danielle Meyrick to Lead Medical Team
MTTI Announces Dr. Danielle Meyrick to Lead Medical Team

Business Wire

time40 minutes ago

  • Business Wire

MTTI Announces Dr. Danielle Meyrick to Lead Medical Team

WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI) today announced the appointment of Danielle Meyrick, PhD, MD, as Chief Medical Officer. Dr. Meyrick brings more than 20 years of medical research, targeted radiotherapeutic (TRT) development and leadership to MTTI. She has held Chief Medical Officer roles across radiopharmaceutical organizations including Telix Pharmaceuticals and ITM Radiopharm. Dr. Meyrick will lead MTTI's medical team to advance clinical development of lead assets, EVA101 and EVA 102 and further progress the company's radiopharmaceutical pipeline. 'My career goal in the TRT area has always been to improve care and outcomes for cancer patients. I believe MTTI is an exciting company with technology that is able to deliver on this goal. Our unique EvaThera platform has demonstrated the ability to enhance delivery of radiation to tumors, minimize off-target activity and reduce dosing requirements —collectively offering a potentially safer, more effective approach to TRT. I am thrilled to be supporting the team in leading EVA101 and EVA102 through the critical final stages of development,' said Danielle Meyrick, CMO of MTTI. Dr. Chris Pak, President & CEO commented 'MTTI is delighted to welcome Dr. Danielle Meyrick, an experienced clinician and executive. Her perspective and track record in TRT development are key complements to our team as we expedite advancement of our targeted radiotherapeutic pipeline.' Molecular Targeting Technologies, Inc. (MTTI). MTTI is a private, clinical stage biotech developing targeted radiotherapeutics (TRT). MTTI is committed to building value by translating innovative TRT to improve human healthcare. For more information:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store